Skip to main content

Table 1 Characteristics of the CUP patients for which the humoral response was evaluated

From: Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

Characteristic

n

Percentage

Age

 ≥ 50

30

73%

 < 50

11

27%

Sex

 Female

25

61%

 Male

16

39%

Primary tumor site a

 Ovary

9

22%

 Breast

4

10%

 Colon

3

7%

 Soft tissues

3

7%

 Brain

3

7%

 Lymphatic system

3

7%

 Lung

2

5%

 Kidney

2

5%

 Uterus

2

5%

 Rectum

2

5%

 Others

8

20%

Metastases b

 With metastatic disease

27

66%

 Without metastases

14

34%

Metastatic sites c

 Lung

10

26%

 Lymph nodes

7

18%

 Peritoneum

5

13%

 Liver

5

13%

 Bone

4

10%

 Brain

3

8%

 Ovary

2

5%

 Others

3

8%

  1. Patients diagnosed with solid tumors or hematologic malignancies were included in the CUP after completing all steps of the recruiting process. aat the time of initial diagnosis; b metastases at the time of enrollment; c metastatic sites found in 27 patients with metastatic disease
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us